Your browser doesn't support javascript.
loading
End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study.
van Breeschoten, Jesper; Ismail, Rawa K; Wouters, Michel W J M; Hilarius, Doranne L; de Wreede, Liesbeth C; Haanen, John B; Blank, Christian U; Aarts, Maureen J B; van den Berkmortel, Franchette W P J; de Groot, Jan Willem B; Hospers, Geke A P; Kapiteijn, Ellen; Piersma, Djura; van Rijn, Rozemarijn S; Stevense-den Boer, Marion A; van der Veldt, Astrid A M; Vreugdenhil, Gerard; Boers-Sonderen, Marye J; Suijkerbuijk, Karijn P M; van den Eertwegh, Alfons J M.
Afiliación
  • van Breeschoten J; Dutch Institute for Clinical Auditing, Leiden, the Netherlands.
  • Ismail RK; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Wouters MWJM; Dutch Institute for Clinical Auditing, Leiden, the Netherlands.
  • Hilarius DL; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands.
  • de Wreede LC; Dutch Institute for Clinical Auditing, Leiden, the Netherlands.
  • Haanen JB; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Blank CU; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.
  • Aarts MJB; Department of Pharmacy, Rode Kruis Ziekenhuis, Beverwijk, the Netherlands.
  • van den Berkmortel FWPJ; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.
  • de Groot JWB; Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Hospers GAP; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
  • Piersma D; Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • van Rijn RS; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Stevense-den Boer MA; Department of Medical Oncology, GROW School for Oncology and Developmental Biology. Maastricht University Medical Center, Maastricht, the Netherlands.
  • van der Veldt AAM; Department of Medical Oncology, Zuyderland Medical Center Sittard, Sittard-Geleen, the Netherlands.
  • Vreugdenhil G; Isala Oncology Center, Isala, Zwolle, the Netherlands.
  • Boers-Sonderen MJ; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Suijkerbuijk KPM; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
  • van den Eertwegh AJM; Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands.
JCO Oncol Pract ; 18(10): e1611-e1620, 2022 10.
Article en En | MEDLINE | ID: mdl-35944229
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Melanoma Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: JCO Oncol Pract Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Melanoma Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: JCO Oncol Pract Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos